B - Reproducibility in preclinical research

Freedman LP, Cockburn IM, Simcoe TS. The economics of reproducibility in preclinical research. PLoS Biology 2016;13(6):e1002165
(doi: 10.1371/journal.pbio.1002165)

 

Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50% in the United States alone. The authors outline a framework for solutions and a plan for long-term improvements in reproducibility rates that will help to accelerate the discovery of life-saving therapies and cures.
http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002165